[2] Fisher B，Dignam J，bryant J，et al. Five versus more than five years of tamoxifen for lymph node negative breast cancer: updated findings from the National Surgical Adjuvant breast and Bowel Project B214 randomized trial [J]. J Natl Cancer Inst，2001，93 (9): 684-690.
[2] 余科达，狄根红，吴炅，等. Er(-) Pr(+ ) 乳腺癌辅助内分泌 治疗的疗效[J]. 中国癌症杂志, 2006，1 6(11): 1011-1015.
[3] Peto r，Davies C. ATLAS (Adjuvant Tamoxifen，Longer Against Shorter ): international among 11 500 women preliminary result [J]. Annual San Antonio breast Cancer Symposium，2007，13 (1): 16-48.
[4] Group TAT. Anastrozole alone or in combination with ta-moxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancr: first results of the ATAC randomised trial[J]. Lancet，2002，3 59(9324): 2131-2139.
[5] Forbes JF，Cuzick J，Buzdar A，et al. Effect of anastrozole and tamoxifen as aduvant treatment for earlystage breast cancer: 100-month analsis of the ATAC trial[J]. Lancet Oncol，2008，9(1): 45-53.
[6] Thurlimann B，Keshaviah A，Coates AS，et al. A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer[J]. N Engl Med，2005，3 53(26): 2747-2757.
[7] Coates AS，Keshaviah A，Thrlimann B，et al. Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1-98[J]. J Clin Oncol，2007，25 (5): 486-492.
[8] Goss PE, Ingle JN，Pater JL, et al，Late extended ajuvant treatment with letrozole improves outcome in women with early stage breast cancer who complete 5 years of tamoxifen[J]. J Clin Oncol，2008, 26(12): 1948-1955.
[9] Kurosumi M，Takatsuka Y，Watanabe T，et al. Histopathological assessment of anastrozole and tamoxifen as preoperative (neoadjuvant) treatment in postmenopausal Japanese women with hormone recep tor-positive breast cancer in the PrOACT trial [J]. J Cancer res Clin Oncol，2008，1 34(6): 715-722.
[10] Gralow Jr，Burstein HJ，Wood W. Preoperative therapy in invasive breast cancer: pathologic assessment and systemic therapy issues in operable disease[J]. J Clin Oncol, 2008, 26(5): 814-819.
[11] 王晓红，章爱斌，倪俊，等. 来曲唑在绝经后乳腺癌患者新辅助 化疗中的应用价值探讨[J]. 浙江医学, 2006，6 (6): 90-91.
[12] Milla-Santos A，Milla L，Calvo N，et al. A nastroloze as neoadjuvant therapy for patients with hermene-dependent, locallyadvanced breast cancer[J]. Anticancer res，2004，24 (2C): 1315-1318.
[13] Smith IE，Dowestt M，Ebbs Sr，et al. Neoadjuvant treatment of postmenopausal breast cancer with anastrozole, tamoxifen，or both in combination: the Immediate Preoprative Anastrozole, Tamoxifen，or Com-bined with Tamoxifen (MPACT) multicenter doubleblind randomized trial[J]. J Clin Oncol，2005，23 (22): 5108-5116.
[14] 王圆，叶剑飞，方文星. Er +/ Pr +、Er +/ Pr-乳腺癌的临床 病理特征及预后分析[J]. 现代肿瘤医学，2 009，4 (4): 1-4.
[15] Dowsett M，Allred C，Knox J，et al. relationship between quantitativeestrogen and progesterone receptor expression and human epidermal growthfactor receptor2 (HEr-2 ) status with recurrence in the Arimidex，Tamoxifen，Alone or in combination trial[J]. J Clin Oncol, 2008, 26(7): 1059-1065.
[16] 赵玉斌，张少华，张积仁，等. Er、Pr 和EphA2 在乳腺癌中的 表达及临床意义[J]. 实用肿瘤杂志，2 010, 25(1): 41-44.
[17] Kaufmann M，Hortobagyi GN，Goldhirsch A, et al. recommenddations from an intemational expect panel on the use of neoadjuvant (primary) systemic treatment of operable breast cancer an update [J]. J Clin Oncol，2006, 24(12): 1940-1949.
[18] Eiermann W，Paepke S，Appfelstaed T，et al. Preoperative treatment of postmenop ausal breast cancer patients with letrozole: a randomized double blind multicenter study[J]. Ann Oncol, 2001，1 2(11): 1527-1532.
[19] Goss PE，Bondarenko IN，Manikhas GN，et al. Phase 3 study of atamestane + toremifene vs. Letrozole in advanced breast cancer [J]. J Clin Oncol, 2006, 24(18 suppl): LBA 525.
[20] Beresford MJ，ravichandran D，Makris A. Neojuvant endocrine therapy in breast cancer[J]. Cancer Treat rev，2007，33 (1 ): 48-57.
[21] Cheung KL，Hawell A，robertson JF, et al. Preoperative endocrine therapy for breast cancer[J]. Endocr Cancer，2007，7 (3 ): 131-141.
[22] Ellis MJ. Preoperative endocrine therapy for older women with breast cancer. renewed intereat in an old idea [J]. Cancer Control，2007，7 (6): 557-562.